Sugi Predict

Sugi Predict / Compounds / SCHEMBL1342985

SCHEMBL1342985

SCHEMBL1342985

O=c1[nH]c(=S)[nH]c2ccccc12

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 7/20 0.63
▸ PARP1 P09874 4/20 0.63
▸ CA12 O43570 1/20 0.63
▸ CA9 Q16790 1/20 0.63
▸ ALDH1A1 P00352 7/20 0.59
▸ KMT2A Q03164 4/20 0.59
▸ HSD17B10 Q99714 3/20 0.59
▸ MEN1 O00255 3/20 0.59
▸ LMNA P02545 2/20 0.59
▸ GPR3 P46089 2/20 0.59
▸ TNKS O95271 1/20 0.59
▸ CYP1A2 P05177 1/20 0.59
▸ BLM P54132 1/20 0.59
▸ PMP22 Q01453 1/20 0.59
▸ PARP15 Q460N3 1/20 0.59
▸ TNKS2 Q9H2K2 1/20 0.59
▸ MAPT P10636 3/20 0.58
▸ CYP3A4 P08684 1/20 0.58
▸ PSMB8 P28062 1/20 0.58
▸ TDP1 Q9NUW8 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29446348 1.00 KDM4E (0.63) KDM4EPARP1CA12CA9ALDH1A1
SCHEMBL8873438 0.79 PARP1 (0.74) KDM4EPARP1CA12CA9ALDH1A1
Benzoylenurea SCHEMBL29407209 0.77 KDM4E (1.00) KDM4EPARP1CA12CA9ALDH1A1
Benzoylenurea SCHEMBL37945 0.77 KDM4E (1.00) KDM4EPARP1CA12CA9ALDH1A1
SCHEMBL2680080 0.77 KMT2A (0.64) KDM4EPARP1ALDH1A1KMT2AHSD17B10
Benzoylenurea SCHEMBL5072763 0.76 KDM4E (0.95) KDM4EPARP1CA12CA9ALDH1A1
Benzoylenurea SCHEMBL29722891 0.76 KDM4E (0.95) KDM4EPARP1CA12CA9ALDH1A1
Benzoylenurea SCHEMBL30526893 0.76 KDM4E (0.95) KDM4EPARP1CA12CA9ALDH1A1
2-Mercaptobenzimidazole SCHEMBL29360590 0.75 ALDH1A1 (1.00) KDM4EALDH1A1KMT2AHSD17B10MEN1
2-Mercaptobenzimidazole SCHEMBL705730 0.75 ALDH1A1 (1.00) KDM4EALDH1A1KMT2AHSD17B10MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117802586-A Synthesis method of On-DNA 2-thioquinazolinone compound 重庆大学 2024-04-02 — — CN claimed
CN-113354592-B 2-thioquinazolinone compound and preparation method and application thereof 赣南师范大学 2022-06-21 — — CN claimed
CN-113354592-A 2-thioquinazolinone compound and preparation method and application thereof 赣南师范大学 2021-09-07 — — CN claimed
US-20210038589-A1 USES, COMPOSITIONS AND METHODS FISAHN ANDRE (SE) 2021-02-11 — — US claimed
EP-3765082-A1 USES, COMPOSITIONS AND METHODS Fisahn, André (SE) 2021-01-20 — — EP claimed
WO-2019175395-A1 USES, COMPOSITIONS AND METHODS FISAHN ANDRE (SE) 2019-09-19 — — WO claimed
US-20100152213-A1 COMPOUND THAT IS A DUAL INHIBITOR OF ENZYMES PDE7 AND/OR PDE4, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) 2010-06-17 — — US claimed
EP-2130823-A1 COMPOUND THAT IS A DUAL INHIBITOR OF ENZYMES PDE7 AND/OR PDE4, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF Consejo Superior De Investigaciones Científicas (ES) 2009-12-09 — — EP claimed
US-12435092-B2 Substituted imidazo[1,2-A]quinazolines as inhibitors of PARG 858 THERAPEUTICS, INC. (US) 2025-10-07 — — US disclosed
WO-2025111492-A1 INHIBITORS OF PARG 858 THERAPEUTICS, INC. (US) 2025-05-30 — — WO disclosed
US-20250146050-A1 STABILISATION OF BIOLOGICAL SAMPLES QIAGEN GMBH (DE) 2025-05-08 — — US disclosed
US-20250122555-A1 STABILISATION OF BIOLOGICAL SAMPLES QIAGEN GMBH (DE) 2025-04-17 — — US disclosed
EP-4526304-A1 INHIBITORS OF PARG 858 Therapeutics, Inc. (US) 2025-03-26 — — EP disclosed
US-12139744-B2 Stabilisation of biological samples QIAGEN GMBH (DE) 2024-11-12 — — US disclosed
EP-0946095-A1 FUNGICIDAL QUINAZOLINONES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1999-10-06 — — EP disclosed
WO-1998026664-A1 FUNGICIDAL QUINAZOLINONES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1998-06-25 — — WO disclosed
EP-0387086-A2 Photoinitiator compositions, photohardenable compositions containing the same THE MEAD CORPORATION (US) 1990-09-12 — — EP disclosed
US-4854965-A SUBSTITUTED 2,4-DIOXO-AND 2,4-DITHIO-1,3-DIHYDROQUINAZOLINES; CONTROLLING BROAD-LEAFED WEEDS IN CEREAL CROPS MAKHTESHIM CHEMICAL WORKS, LTD. (IL) 1989-08-08 — — US disclosed
EP-0254049-A2 Herbicidal compositions MAKHTESHIM CHEMICAL WORKS LIMITED (IL) 1988-01-27 — — EP disclosed
US-4551458-A 1-HALOALKYLTHIO DERIVATIVES MAKHTESHIM CHEMICAL WORKS, LTD. (IL) 1985-11-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12435092-B2 Substituted imidazo[1,2-A]quinazolines as inhibitors of PARG PARG, PLG, PTGIS KDM4E 3367/4885PARP1 45/4885CA12 4697/4885
US-20250122555-A1 STABILISATION OF BIOLOGICAL SAMPLES RNASE1, RNASEH1, EWSR1 KDM4E 3529/4885PARP1 555/4885CA12 781/4885
US-20210038589-A1 USES, COMPOSITIONS AND METHODS APP, CACNA1G, CACNA1B KDM4E 4234/4885PARP1 3853/4885CA12 430/4885
US-12139744-B2 Stabilisation of biological samples RNASE1, RNASEH1, EWSR1 KDM4E 3529/4885PARP1 555/4885CA12 781/4885
US-20100152213-A1 COMPOUND THAT IS A DUAL INHIBITOR OF ENZYMES PDE7 AND/OR PDE4, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF PDE4B, PDE7B, PDE12 KDM4E 376/4885PARP1 1315/4885CA12 1678/4885
US-20250146050-A1 STABILISATION OF BIOLOGICAL SAMPLES RNASE1, RNASEH1, EWSR1 KDM4E 3529/4885PARP1 555/4885CA12 781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.